UAE Artificial Intelligence In Cancer Diagnostics Market By Component Type (Software, Hardware, and Services), By Diagnosis Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumour, and Others), By End User (Hospitals, Surgical Centres & Medical Institutes, and Others), By Region, Competition, Forecast and Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 0.56 Million
CAGR (2026-2031)	16.78%
Fastest Growing Segment	Software
Largest Market	Dubai
Market Size (2031)	USD 1.42 Million

Market Overview

The UAE Artificial Intelligence In Cancer Diagnostics Market will grow from USD 0.56 Million in 2025 to USD 1.42 Million by 2031 at a 16.78% CAGR. Artificial intelligence in cancer diagnostics encompasses the application of advanced algorithms and machine learning models to analyze medical data, such as imaging, pathology, and genomics, facilitating earlier and more accurate cancer detection and characterization. This market's growth in the UAE is primarily driven by substantial government initiatives promoting digital transformation in healthcare and the rising prevalence of cancer cases necessitating enhanced diagnostic precision. According to the Ministry of Health and Prevention (MOHAP), in June 2026, a 35% year-on-year increase in investment within the healthcare technology sector was reported, primarily driven by advancements in AI-powered diagnostics.

Further market drivers include increasing awareness regarding the importance of early disease detection and the growing emphasis on personalized medicine approaches in oncology. These factors are accelerating the integration of AI tools for predictive analytics and tailored treatment strategies. However, a significant challenge impeding market expansion involves ensuring the privacy and security of sensitive medical data as AI systems process vast amounts of patient information.

Key Market Drivers

Government Investment in AI-Enabled Cancer Diagnostics
Robust government initiatives and digital transformation in healthcare are profoundly influencing the UAE Artificial Intelligence in Cancer Diagnostics Market. The UAE government, through entities like the Ministry of Health and Prevention and the Department of Health – Abu Dhabi, is actively fostering an environment conducive to technological integration in healthcare. These efforts include significant investments in digital infrastructure and the promotion of AI-powered services to enhance diagnostic capabilities and patient outcomes. For instance, according to Arabian Business, in May 2026, the Abu Dhabi government allocated AED 13 billion to its Digital Strategy (2025–2027), which encompasses over 200 AI-enabled services aimed at transforming healthcare governance. This strategic financial commitment directly supports the development and deployment of AI solutions for early and accurate cancer detection.

Rising Cancer Burden and AI Adoption in Diagnostics
Concurrently, the rising incidence of cancer cases and an aging population represent a substantial driver for the adoption of AI in cancer diagnostics across the UAE. The increasing burden of cancer necessitates advanced diagnostic tools capable of improving detection rates and supporting personalized medicine approaches. According to The National, in June 2025, earlier that year, the Ministry of Health and Prevention reported 7,487 new incidents of cancer were found in 2023, underscoring the growing prevalence of the disease. This demographic shift, coupled with an escalating demand for early and precise diagnoses, pushes healthcare providers to integrate AI technologies that can analyze complex medical data more efficiently. The widespread acceptance of such technologies is evident, as according to the 2026 Edelman Trust Barometer Special Report, in June 2026, 59% of respondents in the UAE use AI to manage their health, indicating high public confidence and integration into everyday healthcare decision-making within the nation.

Download Free Sample Report

Key Market Challenges

Data Privacy and Security as Adoption Barriers
A significant challenge impeding the expansion of the UAE Artificial Intelligence in Cancer Diagnostics Market involves ensuring the privacy and security of sensitive medical data as AI systems process vast amounts of patient information. This critical concern directly affects the willingness of healthcare providers and patients to fully adopt AI diagnostic tools, thereby slowing market penetration and growth. The inherent sensitivity of health records, coupled with stringent data protection regulations in the UAE, creates a cautious environment for innovation.

Escalating Cyber Threats and Privacy Risks in Healthcare AI
This challenge is exacerbated by a persistent threat landscape. According to the UAE Cyber Security Council, since the beginning of 2025, over 12,000 Wi-Fi breaches were recorded in the UAE, representing approximately 35% of all cyberattacks in the country, with healthcare identified as an exposed sector. Such a high volume of security incidents fosters apprehension among stakeholders regarding the safeguarding of highly confidential cancer diagnostic data, including genomic and pathological information. Organizations become hesitant to integrate advanced AI solutions that necessitate extensive data sharing and processing, fearing potential breaches and the severe consequences for patient confidentiality and institutional reputation.

Key Market Trends

AI-Enhanced Medical Imaging in UAE Cancer Diagnostics
A significant trend shaping the UAE Artificial Intelligence in Cancer Diagnostics Market is the enhancement of medical imaging through AI. This involves deploying advanced AI algorithms to improve the clarity, detail, and interpretability of radiological scans such as MRI, CT, and X-rays. These enhancements aid radiologists in detecting subtle anomalies that might be missed by the human eye, thereby facilitating earlier and more precise cancer diagnoses. The technology also reduces the time required for image analysis, increasing diagnostic throughput and alleviating the burden on healthcare professionals. For instance, according to Dr. Tariq Hassan, CEO of a leading healthcare technology startup in Dubai Healthcare City, quoted in Spectronix Consultancy, June 2026, in the 'UAE Healthcare Tech Soars: AI Drives Innovation & Investment Across Emirates', a 15% reduction in misdiagnosis rates has been observed since implementing these AI-powered systems in partner clinics across Dubai.

AI-Driven Digital Pathology for Comprehensive Tissue Analysis
Another impactful trend is the integration of digital pathology with AI for comprehensive tissue analysis. This involves digitizing traditional glass slides of tissue biopsies and applying AI algorithms to analyze pathological features for cancer identification, grading, and prognosis. Digital pathology with AI transforms the workflow for pathologists, enabling remote consultation, automated preliminary analysis, and improved consistency in diagnoses. This technological advancement supports pathologists in making more informed decisions by highlighting critical areas and quantifying disease characteristics with high precision. According to Dr. Aisha Al Muhairi, Director of Digital Health at the Dubai Health Authority, quoted in Spectronix Consultancy, June 2026, in 'UAE Healthcare Tech Soars: AI Drives Innovation & Investment Across Emirates', AI algorithms enhance the accuracy of early disease detection by over 20% across the emirate.

Segmental Insights

Software-Driven AI Diagnostics Spearheading UAE Cancer Diagnostics Market
The Software segment is the fastest growing within the UAE Artificial Intelligence in Cancer Diagnostics Market due to its inherent ability to leverage advanced algorithms and machine learning models. This enables precise and rapid analysis of extensive medical data, including imaging and patient histories, significantly enhancing diagnostic accuracy and facilitating earlier cancer detection. Such capabilities are fundamental to the UAE's national digital transformation agenda in healthcare. Furthermore, proactive government strategies, such as the UAE National AI Strategy 2031, and policies from the Ministry of Health and Prevention, actively encourage the integration of AI. Regulatory bodies like the Dubai Health Authority and the Department of Health Abu Dhabi further accelerate adoption by establishing frameworks that ensure ethical deployment, patient safety, and robust data protection.

Regional Insights

Dubai's Leadership in UAE AI Cancer Diagnostics Driven by Infrastructure and Regulatory Framework.
Dubai leads the UAE Artificial Intelligence in Cancer Diagnostics Market due to its advanced healthcare infrastructure and numerous prominent medical facilities. This dominance is further propelled by strategic investments in healthcare technology and the emirate's commitment to integrating artificial intelligence within its healthcare system. The Dubai Health Authority plays a crucial role with its Artificial Intelligence Policy in Healthcare, which establishes clear regulatory requirements for ethical and safe AI deployment. This policy ensures adherence to patient safety, transparency, accountability, and data protection standards across healthcare facilities and research institutions, fostering a trusted environment for AI innovation in cancer diagnostics. This robust framework, alongside an active research ecosystem, positions Dubai at the forefront of this market.

Recent Developments

• In October 2025, the Department of Health – Abu Dhabi (DoH) unveiled new AI-powered initiatives at GITEX Global, designed to predict and prevent chronic diseases, including cancer. Among these initiatives was the Next-Gen Wellness program, which integrates wearable technology and AI-driven health analysis for early risk detection and personalized wellness plans. Furthermore, the emirate's AI patient risk profiling system, fully operational across all hospitals and clinics, assesses the risk of developing 14 different diseases, including various cancers, by scrutinizing health records. These advancements bolster proactive healthcare in the UAE Artificial Intelligence in Cancer Diagnostics Market.
• In June 2025, M42, a global health technology leader, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to introduce advanced liquid biopsy testing to the UAE. This partnership aimed to revolutionize cancer care by integrating SOPHiA GENETICS' MSK-ACCESS® with SOPHiA DDM™ technology into M42’s testing infrastructure. The initiative was designed to facilitate faster, more accurate biomarker testing across various cancers, inform treatment decisions, and enable real-time monitoring of disease progression. This development enhances precision oncology within the UAE Artificial Intelligence in Cancer Diagnostics Market.
• In March 2025, Lunit, a leading provider of AI-powered solutions for cancer diagnostics, secured a multi-year contract with Abu Dhabi Health Services Company (SEHA), the UAE's largest integrated healthcare network. Under this five-year agreement, Lunit’s AI solution for mammography analysis, Lunit INSIGHT MMG, was deployed across SEHA’s extensive network of hospitals and clinics. This deployment, following a successful proof-of-concept evaluation, is expected to analyze over a hundred thousand mammography images, significantly enhancing breast cancer screening capabilities and improving early detection within the UAE Artificial Intelligence in Cancer Diagnostics Market.
• In April 2024, NGeneBio Co., a South Korean medical diagnostics firm, announced a collaboration with Euro Alliance, a company based in the UAE and Switzerland focused on medical technology commercialization. This partnership involved NGeneBio transferring its next-generation sequencing (NGS) precision diagnostic technology, encompassing products, software, and manufacturing expertise, to Euro Alliance in the UAE. The initiative aimed to establish joint venture operations for NGS in the UAE and India, with NGeneBio set to receive royalties from future sales over a decade. This collaboration contributes to advancing diagnostic capabilities within the UAE Artificial Intelligence in Cancer Diagnostics Market by integrating advanced genomic data analysis.

Key Market Players

• IBM Corporation
• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• Koninklijke Philips N.V.
• Roche Holding AG
• Illumina, Inc.
• Tempus AI, Inc.
• PathAI, Inc.
• Aidoc Medical Ltd.
• Fujifilm Holdings Corporation

By Component Type	By Diagnosis Type	By End User	By Region
Software Hardware and Services	Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumour and Others	Hospitals Surgical Centres & Medical Institutes and Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Artificial Intelligence In Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Artificial Intelligence In Cancer Diagnostics Market, By Component Type:

• Software
• Hardware
• and Services

• UAE Artificial Intelligence In Cancer Diagnostics Market, By Diagnosis Type:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumour
• and Others

• UAE Artificial Intelligence In Cancer Diagnostics Market, By End User:

• Hospitals
• Surgical Centres & Medical Institutes
• and Others

• UAE Artificial Intelligence In Cancer Diagnostics Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE